Subscribe to Our Blog
In the spring of 2019 we attended our first industry event: the Casualty Actuarial Society’s (CAS) Ratemaking, Product and Modeling (RPM) Seminar. RPM serves as a networking event and provides continuing education for CAS members by way of numerous workshops and sessions. We both work on predictive analytics projects, which made this event relevant to our work and solidified our understanding on many of the topics we work on every day, including modeling methods, model testing and implementation.
In recent years, statisticians and researchers have continued to vigorously sound the alarm on the use and abuse of p-values in clinical studies and statistical modeling in general. Look no further than the official statement of the American Statistical Association (ASA), “The ASA’s Statement on p-Values: Context, Process, and Purpose,” that was published just two years ago in response to the ever more heated debate on the confirmatory role of p-values in quantitative science and the validity of statistical inference. While many in the scientific community have generated discussions and commentaries on the misuse of p-values, the ASA’s policy statement succinctly synthesizes “several widely agreed upon principles underlying the proper use and interpretation of the p-value.” The ASA’s statement puts forth six principles aiming to guide practitioners in their search for statistically significant effects, ameliorate the problem of false discovery rates and irreproducibility of results, and thus improve on the applicability of the scientific method.
« Show All Blog Posts